Terms: = Breast cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Prognosis
644 results:
1. Postpartum breast cancer and Survival in Women With Germline BRCA Pathogenic Variants.
Zhang Z; Ye S; Bernhardt SM; Nelson HD; Velie EM; Borges VF; Woodward ER; Evans DGR; Schedin PJ
JAMA Netw Open; 2024 Apr; 7(4):e247421. PubMed ID: 38639936
[TBL] [Abstract] [Full Text] [Related]
2. Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate cancer.
Kalampokis N; Zabaftis C; Spinos T; Karavitakis M; Leotsakos I; Katafigiotis I; van der Poel H; Grivas N; Mitropoulos D
Curr Oncol; 2024 Feb; 31(3):1162-1169. PubMed ID: 38534919
[TBL] [Abstract] [Full Text] [Related]
3. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
[TBL] [Abstract] [Full Text] [Related]
4. Investigation of Genetic Alterations Associated With Interval breast cancer.
Rodriguez J; Grassmann F; Xiao Q; Eriksson M; Mao X; Bajalica-Lagercrantz S; Hall P; Czene K
JAMA Oncol; 2024 Mar; 10(3):372-379. PubMed ID: 38270937
[TBL] [Abstract] [Full Text] [Related]
5. [Does Early Olaparib Administration Improve prognosis in Patients with HER2-Negative Metastatic breast cancer and brca1 and/or BRCA2 Pathogenic Variants?-A Case Report].
Takuwa H; Sasaki S; Yamada T; Takeuchi M
Gan To Kagaku Ryoho; 2023 Dec; 50(12):1295-1299. PubMed ID: 38247067
[TBL] [Abstract] [Full Text] [Related]
6. Establishing the role of brca1 in the diagnosis, prognosis and immune infiltrates of breast invasive cancer by bioinformatics analysis and experimental validation.
Li L; Li S; Zhang X; Mei L; Fu X; Dai M; Wei N
Aging (Albany NY); 2024 Jan; 16(2):1077-1095. PubMed ID: 38224491
[TBL] [Abstract] [Full Text] [Related]
7. Male breast cancer (MBC) - A Review.
AlFehaid M
Pol Przegl Chir; 2023 Dec; 95(6):24-30. PubMed ID: 38058163
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K
J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662
[TBL] [Abstract] [Full Text] [Related]
9. High PGAP3 expression is associated with lymph node metastasis and low CD8
Hao N; Li M; Wang J; Song Y; Zhao Y; Zhang L; Yang X; Chen L; Ma J; Jia Q; Sui F
Pathol Res Pract; 2023 Nov; 251():154890. PubMed ID: 37839361
[TBL] [Abstract] [Full Text] [Related]
10. A drug design strategy based on molecular docking and molecular dynamics simulations applied to development of inhibitor against triple-negative breast cancer by Scutellarein derivatives.
Akash S; Aovi FI; Azad MAK; Kumer A; Chakma U; Islam MR; Mukerjee N; Rahman MM; Bayıl I; Rashid S; Sharma R
PLoS One; 2023; 18(10):e0283271. PubMed ID: 37824496
[TBL] [Abstract] [Full Text] [Related]
11. [Mechanism of Astragali Radix-Curcumae Rhizoma in treating gastric cancer based on network pharmacology and experimental verification].
Tan XY; Tao J; Zhang Y; Gu RX
Zhongguo Zhong Yao Za Zhi; 2023 Sep; 48(18):5056-5067. PubMed ID: 37802848
[TBL] [Abstract] [Full Text] [Related]
12. Prophylactic Salpingo-Oophorectomy and Survival After brca1/2 breast cancer Resection.
Martelli G; Barretta F; Vernieri C; Folli S; Pruneri G; Segattini S; Trapani A; Carolla C; Spatti G; Miceli R; Ferraris C
JAMA Surg; 2023 Dec; 158(12):1275-1284. PubMed ID: 37792368
[TBL] [Abstract] [Full Text] [Related]
13. The Tumor Suppressor brca1/2, cancer Susceptibility and Genome Instability in Gynecological and Mammary cancers.
Oubaddou Y; Ben Ali F; Oubaqui FE; Qmichou Z; Bakri Y; Ameziane El Hassani R
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3139-3153. PubMed ID: 37774066
[TBL] [Abstract] [Full Text] [Related]
14. BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancer.
Ishizuka Y; Horimoto Y; Eguchi H; Murakami F; Nakai K; Onagi H; Hayashi T; Ishikawa T; Arai M; Watanabe J
Breast Cancer Res Treat; 2024 Jan; 203(1):49-55. PubMed ID: 37728693
[TBL] [Abstract] [Full Text] [Related]
15. brca1 and BRCA2 mutations and their clinical relevance in selected women diagnosed with triple-negative breast cancer in Kenya: a descriptive cross-sectional study.
Rioki JN; Muchiri L; Mweu M; Nyagol J; Songok E; Mwangi J; Oyaro M; Ong'ang'o LB; Rogena E
Pan Afr Med J; 2023; 45():102. PubMed ID: 37719058
[TBL] [Abstract] [Full Text] [Related]
16. Mutations of
Tsyganov MM; Sorokovikova SS; Lutzkaya EA; Ibragimova MK
Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628606
[TBL] [Abstract] [Full Text] [Related]
17. Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature.
Ishimoto H; Sakamoto N; Kido T; Ozasa M; Tsutsui S; Mori M; Setoguchi D; Takemoto S; Obase Y; Ishimatsu Y; Tomonaga C; Matsumoto K; Morisaki S; Miura K; Mukae H
BMC Pulm Med; 2023 Aug; 23(1):289. PubMed ID: 37553592
[TBL] [Abstract] [Full Text] [Related]
18. Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer.
Kumari L; Mishra L; Patel P; Sharma N; Gupta GD; Kurmi BD
J Drug Target; 2023 Dec; 31(9):889-907. PubMed ID: 37539789
[TBL] [Abstract] [Full Text] [Related]
19. Identification of PIMREG as a novel prognostic signature in breast cancer via integrated bioinformatics analysis and experimental validation.
Zhao W; Chang Y; Wu Z; Jiang X; Li Y; Xie R; Fu D; Sun C; Gao J
PeerJ; 2023; 11():e15703. PubMed ID: 37483962
[TBL] [Abstract] [Full Text] [Related]
20. Combined low levels of H4K16ac and H4K20me3 predicts poor prognosis in breast cancer.
Wang B; Zhou M; Gan XL; Ren YX; Yang YZ; Weng ZJ; Zhang XF; Guan JX; Tang LY; Ren ZF
Int J Clin Oncol; 2023 Sep; 28(9):1147-1157. PubMed ID: 37428307
[TBL] [Abstract] [Full Text] [Related]
[Next]
